TD Asset Management Inc lowered its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 65.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,368 shares of the company's stock after selling 42,600 shares during the quarter. TD Asset Management Inc's holdings in Spyre Therapeutics were worth $361,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently made changes to their positions in SYRE. BNP Paribas Financial Markets bought a new stake in Spyre Therapeutics during the fourth quarter valued at approximately $437,000. JPMorgan Chase & Co. boosted its stake in shares of Spyre Therapeutics by 19.6% during the 4th quarter. JPMorgan Chase & Co. now owns 35,248 shares of the company's stock worth $821,000 after acquiring an additional 5,775 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Spyre Therapeutics during the 4th quarter valued at $548,000. GAMMA Investing LLC bought a new stake in shares of Spyre Therapeutics during the 1st quarter valued at $70,000. Finally, Northern Trust Corp increased its stake in shares of Spyre Therapeutics by 11.0% in the 4th quarter. Northern Trust Corp now owns 348,983 shares of the company's stock worth $8,124,000 after purchasing an additional 34,693 shares in the last quarter. Institutional investors own 80.39% of the company's stock.
Spyre Therapeutics Stock Up 0.4%
NASDAQ:SYRE traded up $0.06 during trading hours on Friday, hitting $15.30. 117,986 shares of the stock traded hands, compared to its average volume of 620,769. The company has a market cap of $921.98 million, a price-to-earnings ratio of -4.50 and a beta of 2.82. Spyre Therapeutics, Inc. has a 1 year low of $10.91 and a 1 year high of $40.26. The stock has a 50 day moving average price of $16.26 and a 200 day moving average price of $17.00.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.24. Equities analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, Wedbush reiterated an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a research report on Wednesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $53.40.
Check Out Our Latest Analysis on Spyre Therapeutics
Spyre Therapeutics Profile
(
Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Stories
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access